Bristol Piotroski F Score

<div class='circular--portrait' style='background:#689CFD;color: #ffffff;font-size:4em;padding-top: 25px;;'>BM</div>
BMY -- USA Stock  

Report: 6th of August 2020  

This module uses fundamental data of Bristol Myers to approximate its Piotroski F score. Bristol Myers F Score is determined by combining nine binary scores representing 3 distinct fundamental categories of Bristol Myers Squibb. These three categories are profitability, efficiency, and funding. Some research analysts and sophisticated value traders use Piotroski F Score to find opportunities outside of the conventional market and financial statement analysis.They believe that some of the new information about Bristol Myers financial position does not get reflected in the current market share price suggesting a possibility of arbitrage. Continue to Bristol Myers Altman Z Score, Bristol Myers Correlation, Bristol Myers Valuation as well as analyze Bristol Myers Alpha and Beta and Bristol Myers Hype Analysis.

Search Piotroski F Score

 
Refresh
Total Debt is likely to grow to about 50.4 B in 2020. Debt Current is likely to grow to about 3.6 B in 2020. Bristol Myers Asset Turnover is fairly stable at the moment as compared to the past year. Bristol Myers reported Asset Turnover of 0.38 in 2019. Book Value per Share is likely to grow to 34.17 in 2020, whereas Calculated Tax Rate is likely to drop 26.35 in 2020.
5
Piotroski F Score -- Healthy
1
Current Return On Assets
Positive
2
Change in Return on Assets
Increased
3
Cash Flow Return on Assets
Positive
4
Current Quality of Earnings (accrual)
Decreasing
5
Asset Turnover Growth
Increase
6
Current Ratio Change
Decrease
7
Long Term Debt Over Assets Change
Higher Leverage
8
Change In Outstending Shares
Decrease
9
Change in Gross Margin
No Change

Bristol Myers Piotroski F Score Drivers

Current ValueLast YearChange From Last Year 10 Year Trend
Weighted Average Shares1.6 B1.6 B
Sufficiently Down
Decreasing
Slightly volatile
Weighted Average Shares Diluted1.9 B1.7 B
Significantly Up
Increasing
Stable
Net Cash Flow from OperationsB8.1 B
Fairly Down
Increasing
Slightly volatile
Total Assets140.2 B129.9 B
Significantly Up
Increasing
Slightly volatile
Total Liabilities84.4 B78.2 B
Significantly Up
Increasing
Slightly volatile
Current Assets24.5 B29.4 B
Fairly Down
Increasing
Slightly volatile
Current Liabilities15.2 B18.3 B
Significantly Down
Increasing
Slightly volatile
Total Debt50.4 B46.7 B
Significantly Up
Increasing
Slightly volatile
Return on Average Assets0.07260.05
Way Up
Decreasing
Slightly volatile
Gross Margin0.670.691
Sufficiently Down
Decreasing
Slightly volatile
Asset Turnover0.440.377
Fairly Up
Decreasing
Slightly volatile

Bristol Myers Squibb F Score Driver Matrix

Current Sentiment - BMY

Bristol Myers Squibb Investor Sentiment

Predominant part of Macroaxis users are currently bullish on Bristol Myers Squibb. What is your opinion about investing in Bristol Myers Squibb? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Skip

About Bristol Myers Piotroski F Score

F-Score is one of many stock grading techniques developed by Joseph Piotroski, a professor of accounting at the Stanford University Graduate School of Business. It was published in 2002 under the paper titled Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers. Piotroski F Score is based on binary analysis strategy in which stocks are given one point for passing 9 very simple fundamental tests, and zero point otherwise. According to Mr. Piotroski's analysis, his F-Score binary model can help to predict the performance of low price-to-book stocks.

  Weighted Average Shares

Bristol MyersCurrent Valuation Drivers

2014201520162017201820192020 (projected)
Revenue Per Employee635.16 K662.4 K774.96 K876.62 K968.28 K871.5 K774.9 K
Average Assets33.53 B32.27 B33.04 B33.47 B33.61 B69.34 B57.53 B
Earnings before Tax2.36 B2.01 B5.87 B5.16 B5.94 B4.95 B4.63 B
Average Equity15.2 B15 B15.27 B13.91 B13.2 B25.13 B22.34 B
Enterprise Value100.73 B118.06 B101.06 B104.1 B86.74 B99.05 B100.45 B
Free Cash Flow2.62 B1.28 B1.84 B4.22 B4.99 B7.23 B6.09 B
Invested Capital18.77 B19.73 B19.08 B18.46 B17.14 B59.57 B64.27 B
Tangible Asset Value24.97 B23.45 B25.45 B25.48 B27.36 B43.49 B38.07 B
Working Capital6.15 B2.4 B4.86 B5.29 B7.06 B11.05 B9.3 B
Interest Coverage12.7610.2727.7218.4327.979.019.25
Calculated Tax Rate14.7821.4723.881.017.1130.4526.35
PPandE Turnover3.313.533.754.134.164.54.64
Receivables Turnover7.396.045.44.574.324.015.96
Inventory Turnover2.572.814.025.045.552.943.12
Operating Margin16.3211.4123.8317.3922.6922.6223.88
Return on Investment11.228.6621.1216.9624.929.8815.4
Cash Flow Per Share1.91.11.713.253.663.583.03
Revenue to Assets0.420.470.520.580.620.20.21
Quick Ratio1.150.931.171.241.341.261.13
Book Value per Share8.958.559.687.178.631.6734.17
Current Ratio1.521.731.31.551.661.61.54
Debt to Equity Ratio1.541.261.211.851.491.521.57
Dividend Yield0.0330.0250.0220.020.0310.0260.0269
EBITDA Margin0.140.220.180.320.290.260.25

About Bristol Myers Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Bristol Myers Squibb's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Bristol Myers using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Bristol Myers Squibb based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way. Please read more on our fundamental analysis page.
 2017 2018 2019 2020 (projected)
Receivables5.09 B5.35 B7.68 B8.29 B
Inventories1.17 B1.2 B4.29 B4.63 B


 
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page